News & views
Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
For media inquiries, contact us at media@compasspathways.com
October 19, 2021
COMPASS Pathways is granted new US patent for crystalline psilocybin
September 14, 2021
COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs
September 10, 2021
Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds
September 08, 2021
Ecosia: the search engine that plants trees
We've partnered with Ecosia to fund tree-planting projects.
August 18, 2021
Completing our phase IIb clinical trial
An infographic on this significant milestone.
August 13, 2021
White Paper 2021
Our White Paper looks at the state of mental health care in the US, with a focus on treatment-resistant depression.
August 11, 2021
COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021
July 29, 2021
Guy Goodwin joins COMPASS Pathways as Chief Medical Officer
July 21, 2021
Danielle Schlosser joins COMPASS Pathways from Verily Life Sciences to lead clinical innovation and therapist training
July 05, 2021
COMPASS Pathways joins forces with King’s College London and South London and Maudsley NHS Foundation Trust to accelerate psychedelic research and develop new models of mental health care in the UK
June 30, 2021
COMPASS Pathways launches new podcast “Everyone has a story: talking about mental health”
June 28, 2021
COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin therapy trial for treatment-resistant depression
June 23, 2021
COMPASS Pathways becomes Founding Supporter of the British Neuroscience Association’s inaugural Scholars programme
June 11, 2021
COMPASS Pathways plc to participate in JMP Securities and H.C. Wainwright investor conferences
June 03, 2021
COMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers
May 13, 2021
COMPASS Pathways plc announces financial results and business highlights for the first quarter 2021
April 30, 2021
COMPASS Pathways announces pricing of public offering
April 27, 2021
COMPASS Pathways launches proposed public offering
April 15, 2021
New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder
April 12, 2021
COMPASS Pathways plc to participate in 20th Annual Needham Virtual Healthcare Conference
April 01, 2021
COMPASS Pathways appoints Wayne J Riley MD to its Board of Directors
March 23, 2021
COMPASS Pathways granted two US patents
March 09, 2021
Our annual review, with a letter to our shareholders and some highlights from our year
March 09, 2021
COMPASS Pathways plc announces financial results and business highlights for fourth quarter and year-end 2020
March 02, 2021
COMPASS Pathways plc to announce fourth quarter and full year end results
March 01, 2021
COMPASS Pathways plc to participate in Cowen’s 41st Annual Health Care Conference
February 09, 2021
COMPASS Pathways expands its Discovery Center through new collaborations with world-leading scientists
February 03, 2021
COMPASS Pathways announces publication in Frontiers in Psychiatry of paper on therapist training programme for psilocybin therapy
January 28, 2021
COMPASS Pathways plc to participate in Canaccord Genuity’s New Paradigms and Treatment Approaches in Mental Health Conference